Please login to the form below

Not currently logged in
Email:
Password:

Dr Desiree Luthman joins Verona Pharma

She takes up its vice president position

Desiree LuthmanUK-based clinical stage biopharma company Verona Pharma has appointed Dr Desiree Luthman as its vice president of regulatory affairs.

Luthman’s expertise lies in a series of roles leading regulatory affairs teams and strategies for pharmaceutical products spanning from early development to post-approval marketing.

She has also held various regulatory positions for global pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, Celgene and AstraZeneca.

Jan-Anders Karlsson, chief executive officer of Verona Pharma, said: “We welcome Desiree to our growing pharma team.

“She has an accomplished track record of working closely with the FDA and EMA on behalf of international healthcare companies to achieve key regulatory milestones.

“Her vast experience will be instrumental as we advance our regulatory plans in the US and Europe under her leadership in our effort to deliver important new therapies to patients with respiratory diseases.”

Prior to her new role in Verona Pharma, Luthman previously directed regulatory activities related to pulmonary disease at Sanofi and led its regulatory team through the FDA approval of dupilumab for atopic dermatitis in the US.

27th June 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE - Accomplish meaningful HCP engagement via Medthority, our trusted independent medical website. Support education and treatment...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics